This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Genomic Health's CEO Discusses Q2 2012 Results - Earnings Call Transcript

Genomic Health, Inc. (GHDX)

Q2 2012 Earnings Call

August 8, 2012 4:30 pm ET


Emily Faucette – Senior Director, Corporate Communications and Investor Relations

Kimberly Popovits – Chairman of the Board, Chief Executive Officer and President

Bradley Cole – Chief Operating Officer

Dean Schorno – Chief Financial Officer

Steven Shak – Executive Vice President of Research and Development and Chief Medical Officer

Kathy Hibbs – Senior Vice President & General Counsel

Joffre Baker – Chief Scientific Officer

Randal Scott – Founder and Director, Genomic Health and Chief Executive Officer,

InVitae Corporation


Dane Leone – Macquarie Research

Tycho Peterson – JPMorgan

David Clair – Piper Jaffray

Amanda Murphy – William Blair

Dan Leonard – Leerink Swann

Kevin DeGeeter – Ladenburg Thalmann & Co.

Scott Gleason – Stephens Inc.

Laura McGuigan – B. Riley

Nicholas Jansen – Raymond James



Good afternoon. My name is Chuck, and I will be your conference operator today. At this time I would like to welcome everyone to Genomic Health’s Second Quarter 2012 Financial Results Conference Call. All participants are in a listen-only mode. Later we will conduct a question-and-answer session, and instructions will follow at that time. (Operator instructions)

I would now like to turn the call over to Emily Faucette, Senior Director of Corporate Communications and Investor Relations. You may begin your conference.

Emily Faucette

Thank you. Good afternoon everyone and welcome to Genomic Health conference call to review our second-quarter 2012 financial results. Before we begin, I would like to remind you that various remarks that we make on this call that are not historical, including those about our future financial and operating results, our plans and prospects, our ability to leverage our existing infrastructure, the success of our business strategy, economic benefits and value to payers of our tests, growth opportunities, future products, product enhancements and our product pipeline, demand for our tests and drivers of demand, payer coverage and progress in reimbursement and patient access, our investments in our business, clinical outcomes and timing of clinical studies, and product launches, and our expectations regarding our ability to comply with potential FDA regulation constitute forward-looking statements within the meaning of the safe harbor provision of the Private Securities Litigation Reform Act.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs